Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dan Loeb, Third Point Making Moves Last Quarter: Abbott Laboratories (ABT), Electronic Arts Inc. (EA)

Generally speaking, sentiment on this particular segment of healthcare is mixed, though it’s interesting to note that each member of this trio has gained at least 4.5% year-to-date.

At a 4.4% yield, AbbVie pays the highest dividend in S&P 500’s entire healthcare sector, and Abbott offers a much more modest yield of 1.6%. Ariad, meanwhile, is not attractive for income-seeking investors, though Loeb has held the stock since the second quarter of last year. Wall Street’s average price target on Ariad represents an upside of more than 40%, though “monkeys” may be best off by considering all three of these biotech stocks in tandem.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 25.4% between September 2012 and January 2013 versus 7.4% for the S&P 500 index. Try it now by clicking the link above.

Disclosure: none

Loading Comments...